Nippon Shinyaku gains Japanese rights to Labopharm's once-daily tramadol
This article was originally published in Scrip
Executive Summary
The mid-sized Japanese company Nippon Shinyaku has acquired exclusive development and commercial rights in its home market to Labopharm's once-daily oral formulation of the analgesic tramadol.